Bank of America set a GBX 8,500 ($111.07) target price on AstraZeneca (LON:AZN) in a research report report published on Friday, Borsen Zeitung reports. The firm currently has a buy rating on the biopharmaceutical company’s stock.
AZN has been the topic of a number of other research reports. Citigroup reiterated a buy rating and set a £100 ($130.67) target price (up previously from GBX 7,000 ($91.47)) on shares of AstraZeneca in a report on Wednesday, September 11th. Shore Capital reiterated a buy rating on shares of AstraZeneca in a report on Tuesday, August 27th. Deutsche Bank increased their target price on AstraZeneca from GBX 7,600 ($99.31) to GBX 7,800 ($101.92) and gave the company a buy rating in a report on Monday, September 9th. Liberum Capital reiterated a hold rating and set a GBX 6,400 ($83.63) target price on shares of AstraZeneca in a report on Wednesday, August 28th. Finally, Jefferies Financial Group reiterated a neutral rating on shares of AstraZeneca in a report on Thursday, August 29th. Three investment analysts have rated the stock with a sell rating, six have given a hold rating and nine have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of Hold and a consensus target price of GBX 7,050 ($92.12).
Shares of LON:AZN opened at GBX 6,793 ($88.76) on Friday. The business’s fifty day moving average price is GBX 7,160.31 and its two-hundred day moving average price is GBX 6,398.61. The stock has a market cap of $89.12 billion and a PE ratio of 39.68. The company has a debt-to-equity ratio of 144.48, a quick ratio of 0.74 and a current ratio of 0.95. AstraZeneca has a one year low of GBX 5,312 ($69.41) and a one year high of GBX 7,583 ($99.09).
AstraZeneca Company Profile
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Further Reading: The limitations of an equal weight rating
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.